Security
Liminatus Pharma, Inc. Warrants · LIMNW
LIMNWNASDAQWarrantCurrentCIK 1971387Updated Oct 6, 2026
Name history
Iris Parent Holding Corp. · through Feb 7, 2025
LIMNW price & chart
Loading TradingView…
NASDAQ:LIMNW on TradingView ↗About the company
Liminatus Pharma, Inc. (Nasdaq: LIMN) is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company’s portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address unmet needs in cancer treatment.
In the news
No coverage from other publishers is available.
Recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure
Items 3.01, 7.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.01, 3.03, 5.03, 7.01, 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
SCHEDULE 13G - filed by Samda Biolab Co., Ltd. regarding Liminatus Pharma, Inc.
SCHEDULE 13D/A - filed by Valetudo Therapeutics LLC regarding Liminatus Pharma, Inc.
DEF 14A filing
SCHEDULE 13G/A - filed by Ewon Comfortech Co., Ltd. regarding Liminatus Pharma, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 512,795Source | 5,408,859Source |
| Property, Plant and Equipment, NetUSD | 12,221Source | 941Source |
| Current assets: | ||
| Assets, CurrentUSD | 500,574Source | 5,281,643Source |
| Prepaid Expense and Other Assets, CurrentUSD | 162,919Source | 155,501Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 10,327,485Source | 24,748,922Source |
| Stockholders’ equity: | ||
| Common Stock, Value, IssuedUSD | 2,706Source | 1,750Source |
| Additional Paid in CapitalUSD | 29,054,337Source | 9,323,403Source |
| Retained Earnings (Accumulated Deficit)USD | -38,871,733Source | -28,665,216Source |
| Stockholders' Equity Attributable to ParentUSD | -9,814,690Source | -19,340,063Source |
| Liabilities and EquityUSD | 512,795Source | 5,408,859Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 10,298,241Source | 24,748,922Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -10,206,517Source | -3,546,309Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,963,318Source | -1,451,066Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -788,108Source | -2,850,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 13,108Source | — |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,032,762Source | 3,923,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 281,336Source | -378,066Source |
| Supplemental disclosure of cash flow information: | ||
| Income Taxes Paid, NetUSD | 0Source | 0Source |
| Additional Financial Items | ||
| DepreciationUSD | 1,828Source | — |
| General and Administrative ExpenseUSD | 2,967,812Source | 644,619Source |
| InterestExpenseNonoperatingUSD | 215,903Source | 338,882Source |
| Investment Income, InterestUSD | 76,589Source | 122,526Source |
| Net Income (Loss) Attributable to ParentUSD | -10,206,517Source | -3,546,309Source |
| Nonoperating Income (Expense)USD | -7,238,705Source | -216,356Source |
| Operating ExpensesUSD | 2,967,812Source | 3,329,953Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Operating Income (Loss)USD | -2,967,812Source | -3,329,953Source |
| Net Income (Loss) Attributable to ParentUSD | -10,206,517Source | -3,546,309Source |
| Earnings Per Share, BasicUSD per share | -0.43Source | -0.2Source |
| Earnings Per Share, DilutedUSD per share | -0.43Source | -0.2Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 23,753,561Source | 17,500,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 23,753,561Source | 17,500,000Source |
| Interest Expense (non-operating)USD | 215,903Source | 338,882Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 2,967,812Source | 644,619Source |
| Investment Income, InterestUSD | 76,589Source | 122,526Source |
| Nonoperating Income (Expense)USD | -7,238,705Source | -216,356Source |
| Operating ExpensesUSD | 2,967,812Source | 3,329,953Source |
| Research and Development ExpenseUSD | — | 2,685,334Source |
Offerings
Registration 333-296986
Filing attachments
tm2626488d1_ex99-1.htm · 8-K · 2026-09-29
Exhibit 99.1 Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule FULLERTON, Calif., September 29, 2026 - Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule. As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below $1.00 for 30 consecutive business days…
Read attachment ↗tm2623497d1_ex99-1.htm · 8-K · 2026-08-18
EX-99.1 3 tm2623497d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock FULLERTON, CA, August 18, 2026 - Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-50 (the “Reverse Stock Split”), which was approved by stockholders at the…
Read attachment ↗tm2616851d1_ex4-1.htm · 8-K · 2026-06-03
EX-4.1 2 tm2616851d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJEC…
Read attachment ↗tm2616851d1_ex4-2.htm · 8-K · 2026-06-03
EX-4.2 3 tm2616851d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJEC…
Read attachment ↗tm2616851d1_ex99-1.htm · 8-K · 2026-06-03
EX-99.1 5 tm2616851d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds FULLERTON, CA, June 3, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000 shares of common stock of the Company (t…
Read attachment ↗